Loading your page…
Diabetes Mellitus, Type 2
Marketing Authorisation Holder: CHEPLAPHARM Arzneimittel GmbH
EMA Authorisation: 28/07/2006
INN: pioglitazone;metformin
AI Drug & Interaction Analysis
Free account required
Ask Osler about Competact: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.
